IO Biotech enters CEO severance agreement providing 12-18 months pay and equity vesting

IO Biotech, Inc.

Severance pay: 12 months base salary on qualifying termination; 18 months if termination within 6 months pre- or 12 months post-Change in Control.
Equity awards: 12-month vesting acceleration (standard) or 100% vesting at target (Change in Control scenario).
Pro-rated bonus for termination year plus unpaid prior-year bonus; subject to release and non-compete compliance.
CEO Mai-Britt Zocca: addendum to existing service agreement effective June 19, 2025.

item 5.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.